Zacks Research Issues Positive Outlook for Exelixis Earnings

by · The Markets Daily

Exelixis, Inc. (NASDAQ:EXEL – Free Report) – Equities researchers at Zacks Research lifted their FY2027 EPS estimates for Exelixis in a note issued to investors on Thursday, September 3rd. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $3.59 for the year, up from their previous forecast of $3.57. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis’ Q1 2028 earnings at $0.97 EPS.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million during the quarter, compared to analysts’ expectations of $636.40 million. During the same quarter in the previous year, the company earned $0.75 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis.

Other equities analysts have also issued reports about the stock. Citizens Jmp boosted their price target on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Wednesday, June 24th. BMO Capital Markets started coverage on Exelixis in a report on Tuesday, August 18th. They set a “market perform” rating and a $54.00 price target for the company. Wells Fargo & Company increased their price objective on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, July 13th. Royal Bank Of Canada lifted their target price on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Morgan Stanley boosted their price target on shares of Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $50.07.

Get Our Latest Research Report on Exelixis

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $57.67 on Monday. Exelixis has a 1 year low of $33.76 and a 1 year high of $59.72. The business’s 50 day moving average price is $55.23 and its 200-day moving average price is $49.74. The firm has a market capitalization of $14.29 billion, a PE ratio of 18.14, a P/E/G ratio of 1.76 and a beta of 0.42.

Hedge Funds Weigh In On Exelixis

Institutional investors have recently bought and sold shares of the company. Motiv8 Investments LLC acquired a new position in Exelixis during the 4th quarter worth approximately $26,000. Cassaday & Co Wealth Management LLC purchased a new stake in Exelixis during the 1st quarter worth about $27,000. Western Wealth Management LLC acquired a new position in shares of Exelixis in the first quarter valued at approximately $29,000. Acumen Wealth Advisors LLC acquired a new position in Exelixis in the 4th quarter valued at $29,000. Finally, Northwestern Mutual Wealth Management Co. increased its stake in Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. This represents a 37.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by company insiders.

Exelixis Company Profile

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Read More